Takeda Pharmaceutical Company Limited
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

Abstract:

The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.